Did You Know...
...that Thomas Edison's patent application on his phonograph was approved by the Patent Office in just seven weeks? In contrast, it took Gordon Gould, the inventor of the laser, 30 years to obtain his patent -- finally awarded in 1988!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20110300216 | Chewable, swallowable and effervescent solid dosage form for oral delivery of pharmaceutical actives A tablet comprising: (a) an active ingredient; and (b) at least one member of an effervescent couple, wherein said tablet dissolves in water in not more than three minutes and in the mouth in not more than thirty seconds, and wherein said tablet is capable of acting as ... | 12/08/2011 |
| 20110236480 | PREBIOTIC FORMULATIONS AND METHODS OF USE The invention provides methods and pharmaceutical compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and pharmaceutical compositions for improving overall gastrointe... | 09/29/2011 |
| 20110236481 | USE OF SAFFRON AND/OR SAFRANAL AND/OR CROCIN AND/OR PICROCROCIN AND/OR DERIVATIVES THEREOF AS A SATEITY AGENT FOR TREATMENT OF OBESITY Use of saffron and its active ingredients, such as safranal and/or picrocrocin and/or crocin and/or derivatives thereof, for the production of an active satiation agent for the treatment of problems of overweight.... | 09/29/2011 |
| 20110189275 | PTEROSTILBENE COCRYSTALS Cocrystals of pterostilbene are disclosed, including: pterostilbene:caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene:glutaric acid cocrystal, and pterostilbene:piperazine cocrystal. The pterostilbene:caffeine cocrystal is polymorphic. Forms I and... | 08/04/2011 |
| 20110189276 | PTEROSTILBENE COCRYSTALS Cocrystals of pterostilbene are disclosed, including: pterostilbene:caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene:glutaric acid cocrystal, and pterostilbene:piperazine cocrystal. The pterostilbene:caffeine cocrystal is polymorphic. Forms I and... | 08/04/2011 |
| 20110189278 | PTEROSTILBENE COCRYSTALS Cocrystals of pterostilbene are disclosed, including: pterostilbene:caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene:glutaric acid cocrystal, and pterostilbene:piperazine cocrystal. The pterostilbene:caffeine cocrystal is polymorphic. Forms I and... | 08/04/2011 |
| 20110189277 | PTEROSTILBENE COCRYSTALS Cocrystals of pterostilbene are disclosed, including: pterostilbene:caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene:glutaric acid cocrystal, and pterostilbene:piperazine cocrystal. The pterostilbene:caffeine cocrystal is polymorphic. Forms I and... | 08/04/2011 |
| 20110144006 | PROTEIN COMPOSITION The invention relates to a protein composition which upon ingestion by a healthy person with a normal fasting insulin level between 3.0-8.0 μU/L increases the insulin level to at most 20.0 μU/L. The invention may be in the shape of a powder, capsules, pellets, tablets... | 06/16/2011 |
| 20110038929 | ORAL CARE PET PRODUCT AND METHOD An effervescent composition for reducing breath odors and preventing and/or reducing plaque buildup, deposits and/or formation on the teeth of pet animals. The effervescent composition includes at least one active agent adapted to reduce or destroy bacteria present in t... | 02/17/2011 |
| 20100239667 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT Layered pharmaceutical composition suitable for oral use in the treatment of diseases where absorption takes place over a large part of the gastrointestinal tract. The composition comprising A) a solid inner layer comprising i) an active substance, and ii) one or more d... | 09/23/2010 |
| 20100226978 | PH-DEPENDENT CONTROLLED RELEASE PHARMACEUTICAL OPIOID COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising a core, comprising at least one pharmaceutical active ingredient, which is an opioid, wherein the core is coated at least by one coating layer, controlling the release of t... | 09/09/2010 |
| 20100172981 | Ibuprofen-Effervescent Preparation Having a High Dissolution Rate and Method for the Production thereof Effervescent ibuprofen formulations, which contain (a) an active ingredient-containing granule which contains a water-soluble ibuprofen salt and a basic excipient, and (b) an effervescent granule which contains an acid component and a carbon dioxide-forming component, a... | 07/08/2010 |
| 20100047344 | PERFORMANCE ENHANCING COMPOSITION AND USE THEREOF The performance of a mammal, manifested as a reduced oxygen uptake (VO2) during physical exercise, can be enhanced by administering to said mammal a non-toxic amount of nitrate and/or nitrite. Liquid, semi-solid and solid snack and food products and nutrition... | 02/25/2010 |
| 20090280172 | GALENIC FORMULATIONS OF ORGANIC COMPOUNDS The present invention relates to a dosage form for transmucosal administration comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, and an excipient for transmucosal delivery, wherein the active ingredient is present ... | 11/12/2009 |
| 20090220595 | COMBINATION OF ERYTHROPOIETIN GLYCOISOFORMS This invention relates to a combination of erythropoietin glycoisoforms, wherein such glycoisoforms may include a quantity of sialic acid ranging from 4 to 10 molecules of sialic acid per molecule of erythropoietin. The combination of glycoisoforms can be used for the t... | 09/03/2009 |
| 20090202632 | Sublingual Buccal Effervescent A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the m... | 08/13/2009 |
| 20090099142 | PHARMACEUTICAL COMPOSITIONS COMPRISING ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE AND METHOD OF USING SAME The present invention relates generally to pharmaceutical compositions comprising esterified estrogens, methyltestosterone and one or more pharmaceutical excipients. Methods for preparing and using such compositions are also provided.... | 04/16/2009 |
| 20090041842 | Partly Neutralised Anionic (Meth) Acrylate Copolymer The invention relates to a partly neutralised anionic (meth)acrylate copolymer consisting of radically polymerised units containing 25-95% by weight (meth)acrylic acid C1 to C4 alkylesters and 5-75% by weight (meth)acrylate monomer with an anionic ... | 02/12/2009 |
| 20090004269 | Pharmaceutical Composition Comprising a Proton Pump Inhibitor and a Protein Component The present disclosure relates to, inter alia, pharmaceutical compositions comprising a H+K+-ATPase proton pump inhibitor and a protein component; to methods for manufacture of such compositions, and to use of such compositions in treating and prev... | 01/01/2009 |
| 20090004270 | METHOD OF USING GUAVA EXTRACT A method of using guava extract is disclosed that includes administering guava extract to a mammal to inhibit, prevent or alleviate at least one of a headache, nausea, dry mouth, lack of appetite, shakiness, and fatigue. A composition is also disclosed that includes a p... | 01/01/2009 |
| 20080317855 | Particulate Compositions Comprising Alginate and/or Alginic Acid An ingestible particulate composition comprises: a. an alginate and/or alginic acid; b. a bicarbonate and/or carbonate; c. an organic acid; and d. an agglomerant, being a compound, such as a low molecular weight polyol, which allows the particulate composition to flow y... | 12/25/2008 |
| 20080279935 | Composition Comprising a Powder Containing Microencapsulated Polyunsaturated Long-Chain Esterified Fatty Acids Distributed in an Effervescent Base The invention relates to a composition being substantially free from water comprising a powder containing microencapsulated polyunsaturated long-chain esterified fatty acids (PUFA), wherein said PUPA content of said powder is from about 5 to about 50% (w/w), said powder... | 11/13/2008 |
| 20080254110 | Composition For Enhancing Immunity and Reducing Inflammation Related to Infections A composition and method for enhancing immunity and reducing or inhibiting inflammation related innate immune system activation while affording the body of a user protection against known detrimental byproducts of immune-response is provided. The composition comprises a... | 10/16/2008 |
| 20080254079 | NOVEL COMPOSITIONS CONTAINING LYSOZYME AND C-1/C-4 POLYSACCHARIDES AND USE THEREOF IN ORAL CARE, COSMETOLOGY AND DERMATOLOGY, CONTRACEPTION, UROLOGY AND GYNECOLOGY A composition comprising a content of a lysozyme and a content of a C-1/C-4 polysaccharide is useful in oral care, cosmetology and dermatology, contraception, urology and gynecology. It is emphasized that this abstract is provided to comply with the rules requiring an a... | 10/16/2008 |
| 20080213339 | Pharmaceutical Composition Containing Indometacin and/or Acemetacin The invention relates to a pharmaceutically active composition or pharmaceutical form of administering that contains at least one of the active ingredients indomethacin or acemetacin and optionally other adjuvants, the composition containing the active ingredient, or a ... | 09/04/2008 |
| 20080175888 | Combination Therapy Comprising Actinidia and Steroids and Uses Thereof Disclosed is a combination of an Actinidia preparation and one or more steroids, and the use of such a combination to prevent and/or treat allergic and non-allergic inflammatory conditions or diseases, to alleviate at least one symptom of such conditions or disea... | 07/24/2008 |
| 20080175897 | Dosage forms for administering combinations of drugs The present invention is directed to dosage forms that can be used in therapeutic methods involving the oral co-administration of a combination of at least two drugs, one of which impairs gastrointestinal absorption and one of which does not. The dosage forms are design... | 07/24/2008 |
| 20080166396 | Boronate Medicaments Suitable for Short Duration Anticoagulation An oral dosage form of a compound selected from boronic acids which have a neutral thrombin (P1) domain linked to a hydrophobic moiety capable of binding to the thrombin (S2) and (S3) subsites, and salts, prodrugs and prodrug salts of such acids, the dosage form compris... | 07/10/2008 |
| 20080131508 | Oral transmucosal nicotine dosage form The invention described herein relates to an oral transmucosal solid dosage form useful in treating nicotine addiction or as a nicotine substitute or replacement. By virtue of the formulation in combination with nicotine, the invention transmucosally delivers an effecti... | 06/05/2008 |
| 20080102116 | Quick Dissolve Medicament and Method of Manufacturing A medicament core which contains a super disintegrant or an effervescent couple including a foaming agent and a pharmaceutically acceptable acid activator, which core is partially covered by preformed shell coverings shaped to expose at least a part of the core for acti... | 05/01/2008 |
| 20080003272 | Fibrin adhesive granulate and method for its preparation The invention relates to a flowable fibrin adhesive granulate containing thrombin, Factor XIII, fibrinogen, and a calcium salt in the form of granules with a particle size of more than 50 μm to 1000 μm. Said granulate is useful for the healing of wounds in surgery, ti... | 01/03/2008 |
| 20070298078 | Water Soluble Article for Imparting Dietary Fiber to Bottled Water We disclose a tablet containing at least one water-soluble fiber source, wherein the tablet is of a size and shape susceptible to insertion into a package of a beverage and the tablet will dissolve in the beverage in the absence of agitation in less than about 2 minutes... | 12/27/2007 |
| 20070281015 | Anti-acid pharmaceutical composition in powder form and process for making it An anti-acid pharmaceutical composition for the rapid and prolonged neutralization of gastric acidity with mucosa-protecting activity in powder form to prepare, by dispersion in water, a pharmaceutical solution or suspension for oral use characterized in that the compos... | 12/06/2007 |
| 20070281013 | Prednisolone salt formulations The present invention relates to tablets containing prednisolone salts and in particular prednisolone sodium phosphates. The dosage forms include ODTs and non-ODTs, effervescent tablets and noneffervescent tablets and tablets meeting certain performance criteria.... | 12/06/2007 |
| 20070281014 | Prednisolone salt formulations The present invention relates to tablets containing prednisolone salts and in particular prednisolone sodium phosphates. The tablets include ODTs and non-ODTs, effervescent tablets and noneffervescent tablets and tablets meeting certain performance criteria.... | 12/06/2007 |
| 20070224268 | Process for preparing oral calcium compositions A process for the preparation of an orally administrable calcium composition comprising the steps of: (i) obtaining a physiologically tolerable particulate calcium compound having a mean particle size in the range 3 to 40 μm, having a crystalline structure and having a... | 09/27/2007 |
| 20070218131 | EFFERVESCENT FORMULATIONS COMPRISING DESMOPRESSIN An effervescent formulation comprising desmopressin, preferably comprising multilayer effervescent microspheres containing an acidic substance, a basic substance and water-soluble isolating agent. An effervescent formulation comprising desmopressin wherein dissolution i... | 09/20/2007 |
| 20070178150 | Pharmaceutical compositions A pharmaceutical composition in the form of a chewable tablet for the suppression of gastric reflux comprising an alginic acid or salt thereof, a water-soluble carbonate radical precursor, a calcium salt, a first bulk sweetener, and a binding agent. The calcium salt and... | 08/02/2007 |
| 20070178155 | Preparation for gastric buoyant sustained drug release dosage form Disclosed is a floating sustained release pharmaceutical dosage form including a drug that is adapted to release the drug over an extended period of time. The buoyant pharmaceutical dosage form provides extended gastric residence time of the formulation so that substant... | 08/02/2007 |
| 20070166377 | SUSTAINED-RELEASE DRUG FORMULATIONS The present invention relates to a formulation for implantation having a novel constitution, which accomplishes controlled releases of active ingredients. The formulation comprises one of combinations (a), (b) and (c), as well as a carrier comprising a hydrophobic polym... | 07/19/2007 |
